Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)

Next Previous
Trial Profile

Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine (Primary) ; Lamivudine (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms GEN-PRO

Most Recent Events

  • 23 Jan 2030 As table mention on current ART : 3TC or FTC, I have added both as primary. Location is assumed.
  • 28 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top